S100A8/A9 drives monocytes towards M2-like macrophage differentiation and associates with M2-like macrophages in osteoarthritic synovium.

Osteoarthritis S100A8/A9 inflammation macrophage differentiation synovium

Journal

Rheumatology (Oxford, England)
ISSN: 1462-0332
Titre abrégé: Rheumatology (Oxford)
Pays: England
ID NLM: 100883501

Informations de publication

Date de publication:
12 Jan 2024
Historique:
received: 26 07 2023
revised: 04 12 2023
accepted: 21 12 2023
medline: 13 1 2024
pubmed: 13 1 2024
entrez: 12 1 2024
Statut: aheadofprint

Résumé

Macrophages are key orchestrators of the osteoarthritis (OA)-associated inflammatory response. Macrophage phenotype is dependent on environmental cues like the inflammatory factor S100A8/A9. Here, we investigated how S100A9 exposure during monocyte-to-macrophage differentiation affects macrophage phenotype and function. OA synovium cellular composition was determined using flow cytometry and multiplex immunohistochemistry. Healthy donor monocytes were differentiated towards M1- and M2-like macrophages in presence of S100A9. Macrophage markers were measured using flow cytometry and phagocytic activity was determined using pHrodo Red Zymosan A BioParticles. Gene expression was determined using qPCR. Protein secretion was measured using Luminex and ELISA. Macrophages were the dominant leucocyte subpopulation in OA synovium. They mainly presented with a M2-like phenotype, although the majority also expressed M1-like macrophage markers. Long-term exposure to S100A9 during monocyte-to-macrophage differentiation increased M2-like macrophage markers CD163 and CD206 in M1-like and M2-like differentiated cells. In addition, M1-like macrophage markers were increased in M1-like, but decreased in M2-like differentiated macrophages. In agreement with this mixed phenotype, S100A9 stimulation modestly increased expression and secretion of pro-inflammatory markers and catabolic enzymes, but also increased expression and secretion of anti-inflammatory/anabolic markers. In accordance with the upregulation of M2-like macrophage markers, S100A9 increased phagocytic activity. Finally, we indeed observed a strong association between S100A8 and S100A9 expression and the M2-like/M1-like macrophage ratio in end-stage OA synovium. Chronic S100A8/A9 exposure during monocyte-to-macrophage differentiation favours differentiation towards a M2-like macrophage phenotype. The properties of these cells could help explain the catabolic/anabolic dualism in established OA joints with low-grade inflammation.

Identifiants

pubmed: 38216750
pii: 7521400
doi: 10.1093/rheumatology/keae020
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© The Author(s) 2024. Published by Oxford University Press on behalf of the British Society for Rheumatology.

Auteurs

Nienke J T van Kooten (NJT)

Experimental Rheumatology, Radboud University Medical Center, Nijmegen, the Netherlands.
Orthopedics, Canisius Wilhelmina Ziekenhuis, Nijmegen, the Netherlands.

Arjen B Blom (AB)

Experimental Rheumatology, Radboud University Medical Center, Nijmegen, the Netherlands.

Iris J Teunissen van Manen (IJ)

Experimental Rheumatology, Radboud University Medical Center, Nijmegen, the Netherlands.

Wessel F Theeuwes (WF)

Experimental Rheumatology, Radboud University Medical Center, Nijmegen, the Netherlands.

Johannes Roth (J)

Institute of Immunology, University of Münster, Münster, Germany.

Mark A J Gorris (MAJ)

Medical BioSciences, Radboud University Medical Center, Nijmegen, the Netherlands.
Division of Immunotherapy, Oncode Institute, Radboudumc, Nijmegen, the Netherlands.

Birgitte Walgreen (B)

Experimental Rheumatology, Radboud University Medical Center, Nijmegen, the Netherlands.

Annet W Sloetjes (AW)

Experimental Rheumatology, Radboud University Medical Center, Nijmegen, the Netherlands.

Monique M Helsen (MM)

Experimental Rheumatology, Radboud University Medical Center, Nijmegen, the Netherlands.

Peter L E M van Lent (PLEM)

Experimental Rheumatology, Radboud University Medical Center, Nijmegen, the Netherlands.

Sander Koëter (S)

Orthopedics, Canisius Wilhelmina Ziekenhuis, Nijmegen, the Netherlands.

Peter M van der Kraan (PM)

Experimental Rheumatology, Radboud University Medical Center, Nijmegen, the Netherlands.

Thomas Vogl (T)

Institute of Immunology, University of Münster, Münster, Germany.

Martijn H J van den Bosch (MHJ)

Experimental Rheumatology, Radboud University Medical Center, Nijmegen, the Netherlands.

Classifications MeSH